Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | CASR | P41180 | 4/20 | 0.38 |
| ▸ | LAP3 | P28838 | 3/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225738 | 0.85 | CASR (0.46) | CSNK1EF2CASRLAP3ANPEP | |
| SCHEMBL5222018 | 0.83 | CTSD (0.44) | CSNK1EF2CASRLAP3ANPEP | |
| SCHEMBL5225568 | 0.81 | CASR (0.46) | CSNK1EF2CASRLAP3ANPEP | |
| SCHEMBL5222603 | 0.80 | OPRM1 (0.35) | CASR | |
| SCHEMBL5222615 | 0.80 | OPRM1 (0.35) | CASR | |
| SCHEMBL5217674 | 0.80 | CSNK1E (0.49) | CSNK1EF2CASRLAP3ANPEP | |
| SCHEMBL5396321 | 0.79 | CSNK1E (0.51) | CSNK1EF2CASRLAP3ANPEP | |
| SCHEMBL5218444 | 0.77 | CSNK1E (0.47) | CSNK1EF2CASRLAP3ANPEP | |
| Hydrochloric Acid SCHEMBL5217528 | 0.77 | CSNK1E (0.50) | CSNK1EF2CASRLAP3ANPEP | |
| SCHEMBL5217437 | 0.77 | CSNK1E (0.51) | CSNK1EF2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | CSNK1E 1649/4885F2 4696/4885CASR 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.